Why the Stalled Marijuana Hearings and New GAO Report Are a Massive Win for the ADHD Community
By Marilynn Monroe
For the past five years, millions of Americans with ADHD such as myself have lived in a state of chronic survival mode. We’ve watched our lives unravel. Some of us have lost jobs, failed academically, watched our relationships crumble, and suffered through debilitating withdrawals at times because our medications became weak, or completely unavailable altogether.
When hundreds of ADHD patients stood up last December to flood the DEA’s open comment period with raw, painful accounts of how their Aggregate Production Quotas (APQs) were destroying our quality of life, the agency responded with a slap in the face. Their official response was the ultimate bureaucratic shrug: We did nothing wrong. If your meds don’t work, go talk to your doctor.
They tried to frame a systemic ingredient shortage as an individual clinical failure.
Now, the tables have officially turned. A series of monumental legal defeats, scathing government investigations, and quiet backtracking from the DEA have proven what we knew all along: The DEA has been drunk with power, and their law-enforcement overreach into American medicine is on the road to finally collapse.
The Scathing GAO Report: Exposing the Bureaucracy
Our medical treatment should never be dictated by law enforcement bias. The DEA’s systemic discrimination against patients who need controlled substances to function has crossed from a Reddit ‘conspiracy theory’ into an absolute, verifiable fact thanks to the recent Marijuana rescheduling hearings.
The first domino to fall was a highly critical report released by the Government Accountability Office (GAO). The GAO looked directly under the hood of the DEA’s drug scheduling and quota division and confirmed our worst fears: The DEA completely lacks any written policies, standardized roles, or formal procedures for how it evaluates and schedules drugs.
Let that sink in. The agency that holds a monopoly over your brain chemistry and your daily functionality has been making up the rules as they go. The GAO Report effectively proved that the DEA’s quota restrictions are not based on rigorous, repeatable science; they are arbitrary, opaque, and entirely unaccountable.
The Stalled Marijuana Hearings: Confronting Institutional Misconduct
This lack of structured, written policy is exactly what brought the DEA’s massive marijuana rescheduling hearings to a grinding halt. Advocates aggressively challenged the DEA’s opaque participant selection process, accusing the agency of systemic bias and behind-the-scenes collusion. The legal battle reached a boiling point when Chief Administrative Law Judge John Mulrooney II issued a blistering order against the DEA. The judge sharply rebuked the agency for its “unprecedented” and “astonishing” procedural misconduct, writing that the government’s actions were taken in “deliberate defiance of specific direction” from the tribunal.
For years, the DEA has operated as an untouchable entity. Now, their internal misconduct is being laid bare by their own judges. If they cannot even follow the rules in a legal hearing without acting in deliberate defiance of a federal court, how can they be trusted to dictate the manufacturing quotas of life-altering ADHD medications?
The House Oversight Committee Demands Accountability
Our community’s growing outcry has reached the highest levels of government. The House Committee on Oversight and Accountability has aggressively advanced an investigation into the DEA’s mishandling of these critical shortages.
Led by Chairman James Comer and Healthcare Subcommittee Chairwoman Lisa McClain, the committee issued stern warnings to the DEA regarding their complete lack of transparency. In their official letters, the House Oversight Committee demanded that the DEA hand over internal documents and communications explaining why they refused to dynamically adjust manufacturing limits for Schedule II drugs like Adderall, Vyvanse, and Concerta.
Lawmakers explicitly pressed the DEA on why they allowed “stranded quotas” to happen—where manufacturing caps remain locked up by companies unable to produce them, while agile generic drug makers are legally blocked from stepping in to fill the void. The committee even went as far as threatening compulsory legal processes and subpoenas because the DEA was dragging its feet and hiding its metrics.
Connecting the Dots: How Quota Allocation Fueled the Shortage
This congressional pressure cuts straight to the heart of what I exposed on my website regarding the DEA’s quiet modification of Aggregate Production Quotas (APQs). As I documented in my previous investigation, the DEA shifted how it distributed amphetamine active pharmaceutical ingredients (APIs).
Instead of recognizing the FDA-approved 3:1 ratio required to build functional Adderall (75% d-amphetamine to 25% l-amphetamine), the DEA began enforcing an arbitrary, unscientific allocation policy. This bureaucratic miscalculation forced chemical roadblocks onto generic manufacturers, effectively altering the pharmacological outcome of the medication landing on pharmacy shelves.
This is exactly why the shortage crisis has dragged on for so long. As policy experts at the Brookings Institution have pointed out, the DEA relies on a flawed, backward-looking feedback loop. They look at the prior year’s sales to determine the next year’s medical need. But when the DEA’s own quotas artificially restrict supply, sales numbers drop. The DEA then looks at those depressed numbers and assumes “demand is down,” using their own manufactured shortage as justification to freeze or lower quotas further. It is a self-fulfilling prophecy of medical scarcity detailed heavily in Dr. Marta E. WosiÅ„ska’s Full Brookings Policy Analysis.
The Reversal of Chevron Deference: A New Weapon for Patients and Doctors
For decades, the DEA hid behind a legal shield known as Chevron deference, which forced federal courts to automatically defer to an agency’s interpretation of vague laws. If the DEA decided to quietly enforce disastrous quota splits that starved manufacturers of correct raw ingredients, judges simply took the DEA’s word for it.
Not anymore. The Supreme Court’s landmark decision in Loper Bright Enterprises v. Raimondo officially dismantled Chevron deference. Judges—not law enforcement bureaucrats—now have the final say on what the law means.
This is a massive shift in power. If the DEA tries to enforce arbitrary production quotas that directly contradict FDA-approved medical formulations, medical associations, manufacturers, and patient advocacy groups can now sue the DEA in federal court. And this time, the judges won’t be checking with the DEA for answers.
The DEA Tries to Dodge the Blame
In the Federal Register, the DEA officially raised the Aggregate Production Quota for d-amphetamine by several metric tons, explicitly citing an “active-ingredient shortage.”
There it is. In black and white. The very agency that told us our symptoms were in our heads or a matter of “tolerance” was forced to legally admit that the raw bulk ingredients needed to manufacture our medication were missing because of the supply-chain restrictions they enforced.
However, true to form, the DEA attempts a clever blame-shift in the fine print. They argue that if there is a shortage at your local pharmacy, it isn’t because they failed to authorize enough total raw bulk amphetamine chemical for the year.
Instead, they blame individual pharmaceutical factories, claiming these facilities are failing to properly utilize their allocated “dosage-form” quotas to turn that raw powder into finished pills.
The Victory Ahead
To the hundreds of patients who commented last December: Your words were not wasted. By forcing the DEA to respond to us, we legally “exhausted our administrative remedies.”
We created a permanent, un-erasable record of their dismissive arrogance.
That record is now fuel for the congressional committees investigating their quota mismanagement. It is fuel for the federal courts pulling back the reins on administrative overreach.
The DEA was built to enforce criminal law, not to police the clinical scope of American medicine. They have spent years treating patients like collateral damage in an overzealous war on diversion. But between the GAO report, the halted cannabis hearings, the House Oversight probe, and the death of Chevron deference, the walls are closing in on their unilateral power.
We are winning. Slow and steady wins the race. The nightmare isn’t over yet, but the dawn is finally breaking. Keep calling your representatives, keep filing your FDA MedWatch reports, and above all, refuse to be silent.
Sources & Further Reading
- U.S. Drug Enforcement Administration — Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances
Federal Register - U.S. Drug Enforcement Administration — Established Aggregate Production Quotas for Schedule I and II Controlled Substances
Federal Register - U.S. Government Accountability Office — GAO-26-108623
Government Accountability Office - Judge Mulrooney’s Blasting Order — MJBizDaily: Marijuana Rescheduling Judge Blasts DEA for “Astonishing” Behavior
MJBizDaily - Judge Mulrooney’s Order — Cannabis Culture: Marijuana Rescheduling Judge Blasts DEA for “Unprecedented, Astonishing Behavior”
Cannabis Culture - U.S. House Committee on Oversight and Accountability — Request for Information on Shortages of Schedule II Drugs
House Committee on Oversight and Accountability - Brookings Institution — Fixing the Controlled Substance Quota System: Why the Law and the Regulator Must Change
Brookings Institution - Dr. Marta E. Wosińska — DEA to FDA: Quota Policy Analysis
Brookings Institution — Full Policy Analysis (PDF) - Loper Bright Enterprises v. Raimondo
U.S. Supreme Court decision concerning the role of courts in interpreting statutes administered by federal agencies. - Marilynn Monroe — “How DEA Policy Quietly Changed Adderall”
MarilynnMonroe.com